received a capsule containing neither product. Bolusing occurred while cows were "locked-up" immediately after cows returned to the pen after the AM milking. Cows were observed for 5 min following bolusing to ensure against regurgitation.
Milk samples from each cow (from both the AM and PM milking) were collected on d -2, -1, 3, 7, 10, 14, 17, 21, 24 Effects of treatment (1 to 7) and day (-4 or 28) and their interactions were assessed as a completely randomized design using PROC MIXED (SAS Inst. Inc., Cary, NC). A repeated measures analysis with an autoregressive covariance structure and day as the repeated effect was used to determine effects of treatment day and their interaction on repeated measurements (i.e. milk and serum iodine levels, milk yield etc.). Data from this model are represented in the figures. Production data and iodine levels (milk and serum) from d 7 to 14 (2 nd week of supplementation) were combined for each cow and statistically analyzed using the PROC MIXED procedure of SAS. All statistically analyzed data were covariately adjusted using their respective presupplementation (d -4 to -1) values. Results are reported as least squares means and considered different when P ≤ 0.05.
Results and Discussion
Both serum and milk iodine values for the 2 nd week (average of d 7, 10 and 14) are presented in Table 1 . The smallest A dose (30 mg) did not increase (P > 0.05) blood iodine levels (compared to control) but B30 dose increased (P < 0.05) serum insulin 69% (compared to controls). Serum iodine levels did not differ amongst the lowest A or B dose (P > 0.05). Compared to controls and A30, A60 increased (P > 0.05) serum iodine by 106 and 50%, respectively and there were no differences between A60 and B60 (Table 1) . Interesting, B30 was statistically similar (P > 0.05) to both A60 and B60. Both A90 and B 90 had a similar > 2 fold greater serum iodine concentration than controls and both had a 23% increased compared to A60 and B60. There were no differences (P > 0.05) between the time point when (d 10) each dose reach maximum serum levels (Table 2) . Maximum serum iodine levels mirrored that of the 2 nd week average ( Table 2 ). The serum AUC data was similar to the 2 nd week average, indicating that B30 (although not different [P > 0.05] than A30) was similar to A60 and B60. By d 14, both A90 and B90 serum iodine levels were larger (37%; P < 0.05) than the A60 and B60 doses. In every measure, within every dose and within every day, product B always had a numerically higher serum iodine level compared to product A (Table 1 and 2).
In general, the differences between product, dose, day, and temporal pattern were similar in milk iodine concentrations compared to serum iodine levels (Table 1 and 2. Maximum milk iodine levels occurred on d 8 of supplementation but there were no differences amongst product or dose (P > 0.05; Table 2 ). The increase above control levels during the 2 nd week of supplementation for the 30, 60 and 90 mg dose (independent of product) averaged 62, 157 and 293%, respectively (much higher than observed in the serum iodine concentrations; Table 1 and 2) .
No treatment differences in any production parameter measured were detected (Table 1 ). There was no treatment effect on milk SCC (Table 1) or SCS nor was there a relationship between milk iodine levels and SCS. 
